Meeting
2019 ASCO Annual Meeting
ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B cell lymphoma (LBCL).
Authors
Sattva Swarup Neelapu
The University of Texas MD Anderson Cancer Center, Houston, TX
Sattva Swarup Neelapu , Julio C. Chavez , Yi Lin , Javier Munoz , Chaitra Shankar Ujjani , Peter Riedell , Sven De Vos , Olalekan O. Oluwole , Natasha Kekre , Yin Yang , Lovely Goyal , Kate Backhouse , Francesca Milletti , Jun Kawashima , Alex Francisco Herrera
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03761056
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS7574)
DOI
10.1200/JCO.2019.37.15_suppl.TPS7574
Abstract #
TPS7574
Poster Bd #
324a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
First Author: Jason Westin
Poster
2022 ASCO Annual Meeting
Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
First Author: Paolo Strati
Poster
2023 ASCO Annual Meeting
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
First Author: Ian W. Flinn
Poster
2024 ASCO Annual Meeting
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.
First Author: Boyu Hu